SLC5A2 and hydrops fetalis: Our findings suggest that structured HF follow-up, combined with new pharmacological options like SGLT2 inhibitors and finerenone—particularly in HFpEF [10]—may be essential in preventing HF-related hospitalizations in this vulnerable patient population.